AR026066A1 - Particulas virales con epitopos internos exogenos. - Google Patents

Particulas virales con epitopos internos exogenos.

Info

Publication number
AR026066A1
AR026066A1 ARP000105455A ARP000105455A AR026066A1 AR 026066 A1 AR026066 A1 AR 026066A1 AR P000105455 A ARP000105455 A AR P000105455A AR P000105455 A ARP000105455 A AR P000105455A AR 026066 A1 AR026066 A1 AR 026066A1
Authority
AR
Argentina
Prior art keywords
expression
viruses
viral particles
epithopes
peptides
Prior art date
Application number
ARP000105455A
Other languages
English (en)
Spanish (es)
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of AR026066A1 publication Critical patent/AR026066A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8202—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
    • C12N15/8203—Virus mediated transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP000105455A 1999-10-14 2000-10-17 Particulas virales con epitopos internos exogenos. AR026066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924352.9A GB9924352D0 (en) 1999-10-14 1999-10-14 Methods,compositions and applications relating to the generation of novel plant viral particles

Publications (1)

Publication Number Publication Date
AR026066A1 true AR026066A1 (es) 2002-12-26

Family

ID=10862753

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105455A AR026066A1 (es) 1999-10-14 2000-10-17 Particulas virales con epitopos internos exogenos.

Country Status (16)

Country Link
EP (1) EP1235910A1 (zh)
JP (1) JP2003534771A (zh)
KR (1) KR100880477B1 (zh)
CN (2) CN1471580A (zh)
AR (1) AR026066A1 (zh)
AU (1) AU785020B2 (zh)
BR (1) BR0014861A (zh)
CA (1) CA2387626A1 (zh)
CO (1) CO5280142A1 (zh)
CZ (1) CZ20021303A3 (zh)
GB (1) GB9924352D0 (zh)
IL (1) IL149077A0 (zh)
MX (1) MXPA02003789A (zh)
PL (1) PL354933A1 (zh)
WO (1) WO2001027282A1 (zh)
ZA (1) ZA200202815B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000855A2 (en) * 2001-06-21 2003-01-03 Uab Research Foundation Chimeric capsid proteins and uses thereof
KR20050044886A (ko) 2002-07-05 2005-05-13 데니스 르클레르 면역보조 바이러스 입자
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CA2583113C (en) 2004-10-05 2015-11-10 Diversa Corporation Compositions comprising an antigen and a promiscuous t-cell epitope
US20070041999A1 (en) * 2005-06-01 2007-02-22 Lada Rasochova Production of multivalent virus like particles
AU2006270065A1 (en) * 2005-07-19 2007-01-25 Dow Global Technologies Inc. Recombinant flu vaccines
CA2685308A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2013003353A2 (en) * 2011-06-30 2013-01-03 Stc.Unm Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108386D0 (en) * 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
GB9712282D0 (en) * 1997-06-12 1997-08-13 Innes John Centre Innov Ltd Epitope presentation system

Also Published As

Publication number Publication date
MXPA02003789A (es) 2002-09-30
ZA200202815B (en) 2003-08-27
BR0014861A (pt) 2002-07-16
PL354933A1 (en) 2004-03-22
KR100880477B1 (ko) 2009-01-28
CN101591647A (zh) 2009-12-02
EP1235910A1 (en) 2002-09-04
CO5280142A1 (es) 2003-05-30
GB9924352D0 (en) 1999-12-15
WO2001027282A8 (en) 2001-08-16
AU1085201A (en) 2001-04-23
KR20020040868A (ko) 2002-05-30
WO2001027282A1 (en) 2001-04-19
CN1471580A (zh) 2004-01-28
IL149077A0 (en) 2002-11-10
CA2387626A1 (en) 2001-04-19
AU785020B2 (en) 2006-08-24
JP2003534771A (ja) 2003-11-25
CZ20021303A3 (cs) 2002-10-16

Similar Documents

Publication Publication Date Title
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
CO2018005265A2 (es) Vacunas de ácido nucleico para el virus varicela-zóster
PE20110020A1 (es) Inmunomodulacion mediante el uso de celulas madres de la placenta
PE20220379A1 (es) Suministro de biomoleculas a pbmc para modificar una respuesta inmune
ES2103001T3 (es) Vacunas.
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
AR026066A1 (es) Particulas virales con epitopos internos exogenos.
UY30485A1 (es) Uso antiviral de un tensioactivo cationico
ES2263406T1 (es) Produccion de proteina capsida l1 y particulas tipo virus de papilomavirus humano hbv-11.
EA201270191A1 (ru) Лентивирусные векторы, псевдотипированные гликопротеином оболочки вируса синдбис
AR248426A1 (es) Produccion de particulas incorporadas a un virus vegetal que contiene un peptido antigenico, con el fin de preparar una vacuna de virus animal.
AR033574A1 (es) Una cepa bacteriana del grupo de las bacterias lacticas capaces de reducir la tendencia de un individuo a desarrollar reacciones alergicas, las composiciones alimenticias y farmaceuticas que la contienen y las vacunas que la contienen
AR058049A1 (es) Proteina de la capsida del virus dengue inductora de respuesta protectora y composicion farmaceutica
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
AR115069A1 (es) Virus vacuna quimérico sintético
PA8813901A1 (es) Paramixovirus oncolíticos atenuados que codifican citoquinas de aves
WO2007046839A3 (en) New live virus vaccines
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
WO2011150320A3 (en) Activators of innate immunity
IL265524B2 (en) complex glycoproteins
EP1420819A4 (en) SECONDARY VACCINE FOR INFECTIOUS PANCREASCRECIS VIRUS
BRPI0411099A (pt) composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
WO2002038793A3 (en) Hepatitis c virus constructs characterized by high efficiency replication

Legal Events

Date Code Title Description
FB Suspension of granting procedure